Back to Research Hub
Beam Therapeutics Inc.
BEAM
$26.64-0.65 (-2.38%)
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States.
StreetsValue research for Beam Therapeutics Inc. (BEAM)
Members get the full report for Beam Therapeutics Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.